Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update

References

• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688–1700. doi: 10.1056/NEJM200105313442207
   PubMed Web of Science ®Google Scholar
• Mejzini R, Flynn LL, Pitout IL, et al. ALS genetics, mechanisms, and therapeutics: where are we Now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310
   PubMed Web of Science ®Google Scholar
• Boillée S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52(1):39–59. doi: 10.1016/j.neuron.2006.09.018
   PubMed Web of Science ®Google Scholar
• Brown RH, Al-Chalabi A, Longo DL. Amyotrophic lateral sclerosis. Longo DL, editor. N Engl J Med. 2017;377(2):162–172. doi: 10.1056/NEJMra1603471
   PubMed Web of Science ®Google Scholar
• Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80(17):1590–1597. doi: 10.1212/WNL.0b013e31828f18ac
   PubMed Web of Science ®Google Scholar
• Abrahams S. Neuropsychological impairment in amyotrophic lateral sclerosis–frontotemporal spectrum disorder. Nat Rev Neurol. 2023;19(11):655–667. doi: 10.1038/s41582-023-00878-z
   PubMedGoogle Scholar
• Zou Z-Y, Zhou Z-R, Che C-H, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540–549. doi: 10.1136/jnnp-2016-315018
   PubMed Web of Science ®Google Scholar
• Wang H, Guan L, Deng M. Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy. Front Neurosci. 2023;17:1170996.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330(9):585–591. doi: 10.1056/NEJM199403033300901
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7–8):610–617. doi: 10.3109/21678421.2014.959024
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–930. doi: 10.1056/NEJMoa1916945
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099–1110. doi: 10.1056/NEJMoa2204705
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics. 2022;19(4):1248–1258. doi: 10.1007/s13311-022-01237-4
   PubMed Web of Science ®Google Scholar
• Van Daele SH, Masrori P, Van Damme P, et al. The sense of antisense therapies in ALS. Trends Mol Med. 2024;S1471491423002836(3):252–262. doi: 10.1016/j.molmed.2023.12.003
   Google Scholar
• Mathis S, Goizet C, Soulages A, et al. Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci. 2019;399:217–226. doi: 10.1016/j.jns.2019.02.030
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257–268. doi: 10.1016/j.neuron.2011.09.010
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–256. doi: 10.1016/j.neuron.2011.09.011
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gijselinck I, Dillen L, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat. 2013;34(2):363–373. doi: 10.1002/humu.22244
   PubMed Web of Science ®Google Scholar
• Gendron TF, Belzil VV, Zhang Y-J, et al. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol. 2014;127:359–376. doi: 10.1007/s00401-013-1237-z
   PubMedGoogle Scholar
• Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507(7491):195–200. doi: 10.1038/nature13124
   PubMed Web of Science ®Google Scholar
• Levine TP, Daniels RD, Gatta AT, et al. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN rab-GEFs. Bioinformatics. 2013;29(4):499–503. doi: 10.1093/bioinformatics/bts725
   PubMed Web of Science ®Google Scholar
• Zhang D, Iyer LM, He F, et al. Discovery of novel DENN proteins: implications for the evolution of eukaryotic intracellular membrane structures and human disease. Front Genet. 2012;3:283. doi: 10.3389/fgene.2012.00283
   PubMedGoogle Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59–62. doi: 10.1038/362059a0
   PubMed Web of Science ®Google Scholar
• Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264(5166):1772–1775. doi: 10.1126/science.8209258
   PubMed Web of Science ®Google Scholar
• Niwa J, Yamada S, Ishigaki S, et al. Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1. J Biol Chem. 2007;282(38):28087–28095. doi: 10.1074/jbc.M704465200
   PubMed Web of Science ®Google Scholar
• Crow JP, Ye YZ, Strong M, et al. Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L. J Neurochem. 1997;69(5):1945–1953. doi: 10.1046/j.1471-4159.1997.69051945.x
   PubMedGoogle Scholar
• Higgins CMJ, Jung C, Ding H, et al. Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci. 2002;22(6):RC215–RC215. doi: 10.1523/JNEUROSCI.22-06-j0001.2002
   PubMedGoogle Scholar
• Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci. 2002;193(2):73–78. doi: 10.1016/S0022-510X(01)00661-X
   PubMed Web of Science ®Google Scholar
• Ligon LA, LaMonte BH, Wallace KE, et al. Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. Neuroreport. 2005;16(6):533–536. doi: 10.1097/00001756-200504250-00002
   PubMedGoogle Scholar
• Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668–1672. doi: 10.1126/science.1154584
   PubMed Web of Science ®Google Scholar
• Ayala YM, Pantano S, D’Ambrogio A, et al. Human, drosophila, and C.Elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol. 2005;348(3):575–588. doi: 10.1016/j.jmb.2005.02.038
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19(R1):R46–R64. doi: 10.1093/hmg/ddq137
   PubMed Web of Science ®Google Scholar
• Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–611. doi: 10.1016/j.bbrc.2006.10.093
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–133. doi: 10.1126/science.1134108
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobágyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208–1211. doi: 10.1126/science.1165942
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205–1208. doi: 10.1126/science.1166066
   PubMed Web of Science ®Google Scholar
• Bosco DA, Lemay N, Ko HK, et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet. 2010;19(21):4160–4175. doi: 10.1093/hmg/ddq335
   PubMed Web of Science ®Google Scholar
• Rademakers R, Stewart H, Dejesus-Hernandez M, et al. Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle Nerve. 2010;42(2):170–176. doi: 10.1002/mus.21665
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Polymenidou M, Hutt KR, et al. Divergent roles of als-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15(11):1488–1497. doi: 10.1038/nn.3230
   PubMed Web of Science ®Google Scholar
• Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat. 2013;34(6):812–826. doi: 10.1002/humu.22319
   PubMed Web of Science ®Google Scholar
• Qiu H, Lee S, Shang Y, et al. Als-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J Clin Invest. 2014;124(3):981–999. doi: 10.1172/JCI72723
   PubMed Web of Science ®Google Scholar
• Naumann M, Pal A, Goswami A, et al. Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat Commun. 2018;9(1):335. doi: 10.1038/s41467-017-02299-1
   PubMedGoogle Scholar
• Ward S, Thomson N, White JG, et al. Electron microscopical reconstruction of the anterior sensory anatomy of the nematode caenorhabditis elegans.?2UU. J Comp Neurol. 1975;160(3):313–337. doi: 10.1002/cne.901600305
   PubMedGoogle Scholar
• Sulston JE, Horvitz HR. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol. 1977;56(1):110–156. doi: 10.1016/0012-1606(77)90158-0
   PubMed Web of Science ®Google Scholar
• White JG, Southgate E, Thomson JN, et al. The structure of the nervous system of the nematode Caenorhabditis elegans. Philos Trans R Soc Lond B Biol Sci. 1986;314:1–340.
   PubMed Web of Science ®Google Scholar
• Mulcahy B, Witvliet D, Holmyard D, et al. A pipeline for volume electron microscopy of the Caenorhabditis elegans nervous system. Front Neural Circuits. 2018;12:94. doi: 10.3389/fncir.2018.00094
   PubMedGoogle Scholar
• Shaye DD, Greenwald I, Iijima KM. OrthoList: a compendium of C. elegans genes with human orthologs. PLOS ONE. 2011;6(5):e20085. doi: 10.1371/journal.pone.0020085
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen Y, Yu X, et al. Towards understanding neurodegenerative diseases: insights from Caenorhabditis elegans. Int J Mol Sci. 2023;25(1):443. doi: 10.3390/ijms25010443
   PubMedGoogle Scholar
• Baskoylu SN, Yersak J, O’Hern P, et al. Single copy/knock-in models of ALS SOD1 in C. elegans suggest loss and gain of function have different contributions to cholinergic and glutamatergic neurodegeneration. PLOS Genet. 2018;14(10):e1007682. doi: 10.1371/journal.pgen.1007682
   PubMed Web of Science ®Google Scholar
• Gidalevitz T, Krupinski T, Garcia S, et al. Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity. Orr H, editor. PLOS Genet. 2009;5(3):e1000399. doi: 10.1371/journal.pgen.1000399
   PubMed Web of Science ®Google Scholar
• Wang J, Farr GW, Hall DH, et al. An ALS-Linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. Cox GA, editor. PLOS Genet. 2009;5(1):e1000350. doi: 10.1371/journal.pgen.1000350
   PubMed Web of Science ®Google Scholar
• Boccitto M, Lamitina T, Kalb RG, et al. Daf-2 signaling modifies mutant SOD1 toxicity in C. elegans. Blagosklonny MV, editor. PLOS ONE. 2012;7(3):e33494. doi: 10.1371/journal.pone.0033494
   PubMedGoogle Scholar
• Li J, Huang K, Le W. Establishing a novel C. elegans model to investigate the role of autophagy in amyotrophic lateral sclerosis. Acta Pharmacol Sin. 2013;34(5):644–650. doi: 10.1038/aps.2012.190
   PubMed Web of Science ®Google Scholar
• Li J, Li T, Zhang X, et al. Human superoxide dismutase 1 overexpression in motor neurons of Caenorhabditis elegans causes axon guidance defect and neurodegeneration. Neurobiol Aging. 2014;35(4):837–846. doi: 10.1016/j.neurobiolaging.2013.09.003
   PubMed Web of Science ®Google Scholar
• Xu H, Jia C, Cheng C, et al. Activation of autophagy attenuates motor deficits and extends lifespan in a C. elegans model of ALS. Free Radic Biol Med. 2022;181:52–61. doi: 10.1016/j.freeradbiomed.2022.01.030
   PubMed Web of Science ®Google Scholar
• Doonan R, McElwee JJ, Matthijssens F, et al. Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans. Genes Dev. 2008;22(23):3236–3241. doi: 10.1101/gad.504808
   PubMed Web of Science ®Google Scholar
• Liachko NF, Guthrie CR, Kraemer BC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci. 2010;30(48):16208–16219. doi: 10.1523/JNEUROSCI.2911-10.2010
   PubMed Web of Science ®Google Scholar
• Zhang T, Mullane PC, Periz G, et al. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet. 2011;20(10):1952–1965. doi: 10.1093/hmg/ddr076
   PubMed Web of Science ®Google Scholar
• Liachko NF, Saxton AD, McMillan PJ, et al. The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. Acta Neuropathol. 2016;132(4):545–561. doi: 10.1007/s00401-016-1600-y
   PubMed Web of Science ®Google Scholar
• Ash PEA, Zhang Y-J, Roberts CM, et al. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet. 2010;19(16):3206–3218. doi: 10.1093/hmg/ddq230
   PubMed Web of Science ®Google Scholar
• Zhang T, Hwang H-Y, Hao H, et al. Caenorhabditis elegans RNA-processing protein TDP-1 regulates protein homeostasis and life span. J Biol Chem. 2012;287(11):8371–8382. doi: 10.1074/jbc.M111.311977
   PubMedGoogle Scholar
• Saldi TK, Ash PE, Wilson G, et al. TDP -1, the C aenorhabditis elegans ortholog of TDP -43, limits the accumulation of double-stranded RNA. Embo J. 2014;33(24):2947–2966. doi: 10.15252/embj.201488740.
   PubMedGoogle Scholar
• Saldi TK, Gonzales P, Garrido-Lecca A, et al. The Caenorhabditis elegans ortholog of TDP-43 regulates the chromatin localization of the heterochromatin protein 1 homolog HPL-2. Mol Cell Biol. 2018;38(15):e00668–17. doi: 10.1128/MCB.00668-17
   PubMedGoogle Scholar
• Vaccaro A, Patten SA, Ciura S, et al. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio. Le W, editor. PLOS ONE. 2012;7(7):e42117. doi: 10.1371/journal.pone.0042117
   PubMed Web of Science ®Google Scholar
• Vaccaro A, Tauffenberger A, Aggad D, et al. Mutant TDP-43 and FUS cause age-dependent paralysis and neurodegeneration in C. elegans. Petrucelli L, editor. PLOS ONE. 2012;7(2):e31321. doi: 10.1371/journal.pone.0031321
   PubMed Web of Science ®Google Scholar
• Vaccaro A, Patten SA, Aggad D, et al. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiol Dis. 2013;55:64–75. doi: 10.1016/j.nbd.2013.03.015
   PubMed Web of Science ®Google Scholar
• Murakami T, Yang S-P, Xie L, et al. ALS mutations in FUS cause neuronal dysfunction and death in Caenorhabditis elegans by a dominant gain-of-function mechanism. Hum Mol Genet. 2012;21(1):1–9. doi: 10.1093/hmg/ddr417
   PubMed Web of Science ®Google Scholar
• Markert SM, Skoruppa M, Yu B, et al. Overexpression of an als-associated FUS mutation in C. elegans disrupts NMJ morphology and leads to defective neuromuscular transmission. Biol Open. 2020:bio.055129. doi: 10.1242/bio.055129
   PubMedGoogle Scholar
• Labarre A, Tossing G, Maios C, et al. A single copy transgenic mutant FUS strain reproduces age-dependent ALS phenotypes in C. elegans. MicroPubl Biol. 2021;2021. doi: 10.17912/micropub.biology.000473
   PubMedGoogle Scholar
• Baskoylu SN, Chapkis N, Unsal B, et al. Disrupted autophagy and neuronal dysfunction in C. elegans knockin models of FUS amyotrophic lateral sclerosis. Cell Rep. 2022;38(4):110195. doi: 10.1016/j.celrep.2021.110195
   PubMedGoogle Scholar
• Therrien M, Rouleau GA, Dion PA, et al. FET proteins regulate lifespan and neuronal integrity. Sci Rep. 2016;6(1):25159. doi: 10.1038/srep25159
   PubMedGoogle Scholar
• Therrien M, Rouleau GA, Dion PA, et al. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLOS ONE. 2013;8(12):e83450. doi: 10.1371/journal.pone.0083450
   PubMed Web of Science ®Google Scholar
• Corrionero A, Horvitz HR. A C9orf72 ALS/FTD ortholog acts in endolysosomal degradation and lysosomal homeostasis. Curr Biol. 2018;28(10):1522–1535.e5. doi: 10.1016/j.cub.2018.03.063
   PubMed Web of Science ®Google Scholar
• Amick J, Roczniak-Ferguson A, Ferguson SM, et al. C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. Mol Biol Cell. 2016;27(20):3040–3051. doi: 10.1091/mbc.e16-01-0003
   PubMed Web of Science ®Google Scholar
• Sonobe Y, Aburas J, Krishnan G, et al. A C. elegans model of C9orf72-associated ALS/FTD uncovers a conserved role for eIF2D in RAN translation. Nat Commun. 2021;12(1):6025. doi: 10.1038/s41467-021-26303-x
   PubMedGoogle Scholar
• Lamitina T. Length-dependent RNA foci formation and repeat associated non-aug dependent translation in a C. elegans G 4 C 2 model. Micro Publ Biol. 2022;2022. doi: 10.17912/micropub.biology.000600
   Google Scholar
• Rudich P, Snoznik C, Watkins SC, et al. Nuclear localized C9orf72-associated arginine-containing dipeptides exhibit age-dependent toxicity in C. elegans. Hum Mol Genet. 2017;26(24):4916–4928. doi: 10.1093/hmg/ddx372
   PubMedGoogle Scholar
• Ashburner M, Bergman CM. Drosophila melanogaster: a case study of a model genomic sequence and its consequences: fi gu re 1. Genome Res. 2005;15(12):1661–1667. doi: 10.1101/gr.3726705
   PubMed Web of Science ®Google Scholar
• Hales KG, Korey CA, Larracuente AM, et al. Genetics on the fly: a primer on the Drosophila model system. Genetics. 2015;201(3):815–842. doi: 10.1534/genetics.115.183392
   PubMed Web of Science ®Google Scholar
• Adams MD, Celniker SE, Holt RA, et al. The genome sequence of drosophila melanogaster. Science. 2000;287(5461):2185–2195. doi: 10.1126/science.287.5461.2185
   PubMed Web of Science ®Google Scholar
• Myers EW, Sutton GG, Delcher AL, et al. A whole-genome assembly of drosophila. Science. 2000;287(5461):2196–2204. doi: 10.1126/science.287.5461.2196
   PubMed Web of Science ®Google Scholar
• Reiter LT, Potocki L, Chien S, et al. A systematic analysis of human disease-associated gene sequences in drosophila melanogaster. Genome Res. 2001;11(6):1114–1125. doi: 10.1101/gr.169101
   PubMed Web of Science ®Google Scholar
• Pandey UB, Nichols CD, Barker EL. Human disease models in drosophila melanogaster and the role of the fly in therapeutic drug discovery. Barker EL, editor. Pharmacol Rev. 2011;63(2):411–436. doi: 10.1124/pr.110.003293
   PubMed Web of Science ®Google Scholar
• Lloyd TE, Verstreken P, Ostrin EJ, et al. A genome-wide search for synaptic vesicle cycle proteins in drosophila. Neuron. 2000;26(1):45–50. doi: 10.1016/S0896-6273(00)81136-8
   PubMedGoogle Scholar
• Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118(2):401–415. doi: 10.1242/dev.118.2.401
   PubMed Web of Science ®Google Scholar
• McGuire SE, Mao Z, Davis RL. Spatiotemporal gene expression targeting with the TARGET and Gene-switch systems in drosophila. Sci STKE [Internet]. 2004 [cited 2024 Feb 5]. Available from: https://www.science.org/doi/10.1126/stke.2202004pl6
   PubMedGoogle Scholar
• Dietzl G, Chen D, Schnorrer F, et al. A genome-wide transgenic RNAi library for conditional gene inactivation in drosophila. Nature. 2007;448(7150):151–156. doi: 10.1038/nature05954
   PubMed Web of Science ®Google Scholar
• Casci I, Pandey UB. A fruitful endeavor: modeling ALS in the fruit fly. Brain Res. 2015;1607:47–74. doi: 10.1016/j.brainres.2014.09.064
   PubMed Web of Science ®Google Scholar
• Layalle S, They L, Ourghani S, et al. Amyotrophic lateral sclerosis genes in drosophila melanogaster. IJMS. 2021;22(2):904. doi: 10.3390/ijms22020904
   Google Scholar
• Phillips JP, Campbell SD, Michaud D, et al. Null mutation of copper/zinc superoxide dismutase in drosophila confers hypersensitivity to paraquat and reduced longevity. Proc Natl Acad Sci USA. 1989;86(8):2761–2765. doi: 10.1073/pnas.86.8.2761
   PubMed Web of Science ®Google Scholar
• Parkes TL, Elia AJ, Dickinson D, et al. Extension of drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat Genet. 1998;19(2):171–174. doi: 10.1038/534
   PubMed Web of Science ®Google Scholar
• Watson MR, Lagow RD, Xu K, et al. A drosophila model for amyotrophic lateral sclerosis reveals motor neuron damage by human SOD1. J Biol Chem. 2008;283(36):24972–24981. doi: 10.1074/jbc.M804817200
   PubMed Web of Science ®Google Scholar
• Islam R, Kumimoto EL, Bao H, et al. Als-linked SOD1 in glial cells enhances ß-N-Methylamino L-Alanine (bmaa)-induced toxicity in drosophila. F1000Res. 2012;1:47. doi: 10.12688/f1000research.1-47.v1
   PubMedGoogle Scholar
• Kumimoto EL, Fore TR, Zhang B. Transcriptome profiling following neuronal and glial expression of ALS-Linked SOD1 in drosophila. G3 (Bethesda). 2013;3(4):695–708. doi: 10.1534/g3.113.005850
   PubMedGoogle Scholar
• Gallart-Palau X, Ng C-H, Ribera J, et al. Drosophila expressing human SOD1 successfully recapitulates mitochondrial phenotypic features of familial amyotrophic lateral sclerosis. Neurosci Lett. 2016;624:47–52. doi: 10.1016/j.neulet.2016.05.006
   PubMedGoogle Scholar
• Şahin A, Held A, Bredvik K, et al. Human SOD1 ALS mutations in a drosophila knock-in model cause severe phenotypes and reveal dosage-sensitive gain- and loss-of-function components. Genetics. 2017;205(2):707–723. doi: 10.1534/genetics.116.190850
   PubMed Web of Science ®Google Scholar
• Held A, Major P, Sahin A, et al. Circuit dysfunction in SOD1-ALS model first detected in sensory feedback prior to motor neuron degeneration is alleviated by BMP signaling. J Neurosci. 2019;39(12):2347–2364. doi: 10.1523/JNEUROSCI.1771-18.2019
   PubMedGoogle Scholar
• Feiguin F, Godena VK, Romano G, et al. Depletion of TDP‐43 affects drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett. 2009;583(10):1586–1592. doi: 10.1016/j.febslet.2009.04.019
   PubMed Web of Science ®Google Scholar
• Lu Y, Ferris J, Gao F-B. Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Mol Brain. 2009;2(1):30. doi: 10.1186/1756-6606-2-30
   PubMedGoogle Scholar
• Lin M-J, Cheng C-W, Shen C-K, et al. Neuronal function and dysfunction of drosophila dTDP. Marion-poll F, editor. PLOS ONE. 2011;6(6):e20371. doi: 10.1371/journal.pone.0020371
   PubMedGoogle Scholar
• Diaper DC, Adachi Y, Sutcliffe B, et al. Loss and gain of drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum Mol Genet. 2013;22(8):1539–1557. doi: 10.1093/hmg/ddt005
   PubMed Web of Science ®Google Scholar
• Chang J-C, Hazelett DJ, Stewart JA, et al. Motor neuron expression of the voltage-gated calcium channel cacophony restores locomotion defects in a drosophila, TDP-43 loss of function model of ALS. Brain Res. 2014;1584:39–51. doi: 10.1016/j.brainres.2013.11.019
   PubMedGoogle Scholar
• Donde A, Sun M, Ling JP, et al. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 2019;138(5):813–826. doi: 10.1007/s00401-019-02042-8
   PubMed Web of Science ®Google Scholar
• Voigt A, Herholz D, Fiesel FC, et al. TDP-43-Mediated neuron loss in vivo requires RNA-Binding activity. Feany MB, editor. PLOS ONE. 2010;5(8):e12247. doi: 10.1371/journal.pone.0012247
   PubMed Web of Science ®Google Scholar
• Ritson GP, Custer SK, Freibaum BD, et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci. 2010;30(22):7729–7739. doi: 10.1523/JNEUROSCI.5894-09.2010
   PubMed Web of Science ®Google Scholar
• Li Y, Ray P, Rao EJ, et al. A drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci USA. 2010;107(7):3169–3174. doi: 10.1073/pnas.0913602107
   PubMed Web of Science ®Google Scholar
• Ihara R, Matsukawa K, Nagata Y, et al. RNA binding mediates neurotoxicity in the transgenic drosophila model of TDP-43 proteinopathy. Hum Mol Genet. 2013;22(22):4474–4484. doi: 10.1093/hmg/ddt296
   PubMedGoogle Scholar
• Estes PS, Daniel SG, Mccallum AP, et al. Motor neurons and glia exhibit specific individualized responses to TDP-43 expression in a drosophila model of amyotrophic lateral sclerosis. Disease Model Mechanisms. 2013:dmm.010710. doi: 10.1242/dmm.010710
   PubMedGoogle Scholar
• Romano G, Klima R, Buratti E, et al. Chronological requirements of TDP-43 function in synaptic organization and locomotive control. Neurobiol Dis. 2014;71:95–109. doi: 10.1016/j.nbd.2014.07.007
   PubMedGoogle Scholar
• Sreedharan J, Neukomm LJ, Brown RH, et al. Age-dependent TDP-43-Mediated motor neuron degeneration requires GSK3, hat-trick, and xmas-2. Curr Biol. 2015;25(16):2130–2136. doi: 10.1016/j.cub.2015.06.045
   PubMedGoogle Scholar
• Chen Y, Yang M, Deng J, et al. Expression of human FUS protein in drosophila leads to progressive neurodegeneration. Protein Cell. 2011;2(6):477–486. doi: 10.1007/s13238-011-1065-7
   PubMed Web of Science ®Google Scholar
• Lanson NA, Maltare A, King H, et al. A drosophila model of fus-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum Mol Genet. 2011;20(13):2510–2523. doi: 10.1093/hmg/ddr150
   PubMedGoogle Scholar
• Wang J-W, Brent JR, Tomlinson A, et al. The als-associated proteins FUS and TDP-43 function together to affect drosophila locomotion and life span. J Clin Invest. 2011;121(10):4118–4126. doi: 10.1172/JCI57883
   PubMed Web of Science ®Google Scholar
• Xia R, Liu Y, Yang L, et al. Motor neuron apoptosis and neuromuscular junction perturbation are prominent features in a Drosophila model of Fus-mediated ALS. Mol Neurodegener. 2012;7(1):10. doi: 10.1186/1750-1326-7-10
   PubMedGoogle Scholar
• Bogaert E, Boeynaems S, Kato M, et al. Molecular dissection of FUS points at synergistic effect of low-complexity domains in toxicity. Cell Rep. 2018;24(3):529–537.e4. doi: 10.1016/j.celrep.2018.06.070
   PubMedGoogle Scholar
• Machamer JB, Collins SE, Lloyd TE. The ALS gene FUS regulates synaptic transmission at the drosophila neuromuscular junction. Hum Mol Genet. 2014;23(14):3810–3822. doi: 10.1093/hmg/ddu094
   PubMedGoogle Scholar
• Shahidullah M, Le Marchand SJ, Fei H, et al. Defects in synapse structure and function precede motor neuron degeneration in drosophila models of FUS-Related ALS. J Neurosci. 2013;33(50):19590–19598. doi: 10.1523/JNEUROSCI.3396-13.2013
   PubMedGoogle Scholar
• Deng J, Yang M, Chen Y, et al. FUS interacts with HSP60 to promote mitochondrial damage. Lu B,editor. PLOS Genet. 2015;11(9):e1005357. doi: 10.1371/journal.pgen.1005357
   PubMed Web of Science ®Google Scholar
• Altanbyek V, Cha S-J, Kang G-U, et al. Imbalance of mitochondrial dynamics in drosophila models of amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2016;481(3–4):259–264. doi: 10.1016/j.bbrc.2016.10.134
   PubMed Web of Science ®Google Scholar
• Sasayama H, Shimamura M, Tokuda T, et al. Knockdown of the drosophila fused in sarcoma (FUS) homologue causes deficient locomotive behavior and shortening of motoneuron terminal branches. PLOS ONE. 2012;7(6):e39483. doi: 10.1371/journal.pone.0039483
   PubMed Web of Science ®Google Scholar
• Shimamura M, Kyotani A, Azuma Y, et al. Genetic link between cabeza, a Drosophila homologue of fused in sarcoma (FUS), and the EGFR signaling pathway. Exp Cell Res. 2014;326(1):36–45. doi: 10.1016/j.yexcr.2014.06.004
   PubMedGoogle Scholar
• Frickenhaus M, Wagner M, Mallik M, et al. Highly efficient cell-type-specific gene inactivation reveals a key function for the drosophila FUS homolog cabeza in neurons. Sci Rep. 2015;5(1):9107. doi: 10.1038/srep09107
   PubMedGoogle Scholar
• Xu Z, Poidevin M, Li X, et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc Natl Acad Sci USA. 2013;110(19):7778–7783. doi: 10.1073/pnas.1219643110
   PubMed Web of Science ®Google Scholar
• Burguete AS, Almeida S, Gao F-B, et al. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife. 2015;4:e08881. doi: 10.7554/eLife.08881
   PubMed Web of Science ®Google Scholar
• Tran H, Almeida S, Moore J, et al. Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a Drosophila model of C9ORF72 FTD/ALS. Neuron. 2015;87(6):1207–1214. doi: 10.1016/j.neuron.2015.09.015
   PubMed Web of Science ®Google Scholar
• Sharpe JL, Harper NS, Garner DR, et al. Modeling C9orf72-related frontotemporal dementia and amyotrophic lateral sclerosis in drosophila. Front Cell Neurosci. 2021;15:770937. doi: 10.3389/fncel.2021.770937
   PubMedGoogle Scholar
• Mizielinska S, Grönke S, Niccoli T, et al. C9orf72 repeat expansions cause neurodegeneration in drosophila through arginine-rich proteins. Science. 2014;345(6201):1192–1194. doi: 10.1126/science.1256800
   PubMed Web of Science ®Google Scholar
• Wen X, Tan W, Westergard T, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84(6):1213–1225. doi: 10.1016/j.neuron.2014.12.010
   PubMed Web of Science ®Google Scholar
• Yang D, Abdallah A, Li Z, et al. Ftd/als-associated poly(gr) protein impairs the notch pathway and is recruited by poly(ga) into cytoplasmic inclusions. Acta Neuropathol. 2015;130(4):525–535. doi: 10.1007/s00401-015-1448-6
   PubMed Web of Science ®Google Scholar
• Lee K-H, Zhang P, Kim HJ, et al. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167(3):774–788.e17. doi: 10.1016/j.cell.2016.10.002
   PubMed Web of Science ®Google Scholar
• Morón-Oset J, Supèr T, Esser J, et al. Glycine-alanine dipeptide repeats spread rapidly in a repeat length- and age-dependent manner in the fly brain. Acta Neuropathol Commun. 2019;7(1):209. doi: 10.1186/s40478-019-0860-x
   PubMedGoogle Scholar
• Goodman LD, Prudencio M, Kramer NJ, et al. Toxic expanded GGGGCC repeat transcription is mediated by the PAF1 complex in C9orf72-associated FTD. Nat Neurosci. 2019;22(6):863–874. doi: 10.1038/s41593-019-0396-1
   PubMed Web of Science ®Google Scholar
• Moens TG, Niccoli T, Wilson KM, et al. C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. Acta Neuropathol. 2019;137(3):487–500. doi: 10.1007/s00401-018-1946-4
   PubMed Web of Science ®Google Scholar
• Atilano ML, Grönke S, Niccoli T, et al. Enhanced insulin signalling ameliorates C9orf72 hexanucleotide repeat expansion toxicity in drosophila. Elife. 2021;10:e58565. doi: 10.7554/eLife.58565
   PubMedGoogle Scholar
• West RJH, Sharpe JL, Voelzmann A, et al. Co-expression of C9orf72 related dipeptide-repeats over 1000 repeat units reveals age- and combination-specific phenotypic profiles in drosophila. Acta Neuropathol Commun. 2020;8(1):158. doi: 10.1186/s40478-020-01028-y
   PubMedGoogle Scholar
• Freibaum BD, Lu Y, Lopez-Gonzalez R, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525(7567):129–133. doi: 10.1038/nature14974
   PubMed Web of Science ®Google Scholar
• Perry S, Han Y, Das A, et al. Homeostatic plasticity can be induced and expressed to restore synaptic strength at neuromuscular junctions undergoing als-related degeneration. Hum Mol Genet. 2017;26(21):4153–4167. doi: 10.1093/hmg/ddx304
   PubMedGoogle Scholar
• Li S, Wu Z, Li Y, et al. Altered MICOS morphology and mitochondrial ion homeostasis contribute to Poly(GR) toxicity associated with C9-ALS/FTD. Cell Rep. 2020;32(5):107989. doi: 10.1016/j.celrep.2020.107989
   PubMedGoogle Scholar
• Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov. 2005;4(1):35–44. doi: 10.1038/nrd1606
   PubMed Web of Science ®Google Scholar
• Patton EE, Zon LI, Langenau DM. Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials. Nat Rev Drug Discov. 2021;20(8):611–628. doi: 10.1038/s41573-021-00210-8
   PubMed Web of Science ®Google Scholar
• Singh J, Patten SA. Modeling neuromuscular diseases in zebrafish. Front Mol Neurosci. 2022;15:1054573. doi: 10.3389/fnmol.2022.1054573
   PubMedGoogle Scholar
• Lescouzères L, Hassen-Khodja C, Baudot A, et al. A multilevel screening pipeline in zebrafish identifies therapeutic drugs for GAN. EMBO Mol Med. 2023;15(7):e16267. doi: 10.15252/emmm.202216267
   PubMedGoogle Scholar
• Barbazuk WB, Korf I, Kadavi C. The syntenic relationship of the zebrafish and human genomes. Genome Res. 2000;10(9):1351–1358. doi: 10.1101/gr.144700
   PubMed Web of Science ®Google Scholar
• Howe K, Clark MD, Torroja CF, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496(7446):498–503. doi: 10.1038/nature12111
   PubMed Web of Science ®Google Scholar
• Lescouzères L, Bordignon B, Bomont P. Development of a high-throughput tailored imaging method in zebrafish to understand and treat neuromuscular diseases. Front Mol Neurosci. 2022;15:956582. doi: 10.3389/fnmol.2022.956582
   PubMedGoogle Scholar
• Singh J, Pan YE, Patten SA, et al. NMJ analyser: a novel method to quantify neuromuscular junction morphology in zebrafish. Martelli PL, editor. Bioinformatics. 2023;39(12):btad720. doi: 10.1093/bioinformatics/btad720
   PubMedGoogle Scholar
• Eisen JS, Smith JC. Controlling morpholino experiments: don’t stop making antisense. Development. 2008;135(10):1735–1743. doi: 10.1242/dev.001115
   PubMed Web of Science ®Google Scholar
• Schmid B, Haass C. Genomic editing opens new avenues for zebrafish as a model for neurodegeneration. J Neurochem. 2013;127(4):461–470. doi: 10.1111/jnc.12460
   PubMedGoogle Scholar
• Kawakami K, Asakawa K, Hibi M, et al. Gal4 driver transgenic zebrafish. Advances in genetics [Internet]. Elsevier; 2016 [cited 2024 Feb 26]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0065266016300207
   Google Scholar
• Hwang WY, Fu Y, Reyon D, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013;31(3):227–229. doi: 10.1038/nbt.2501
   PubMed Web of Science ®Google Scholar
• Armstrong GAB, Liao M, You Z, et al. Homology directed knockin of point mutations in the zebrafish tardbp and fus genes in ALS using the CRISPR/Cas9 system. PLOS ONE. 2016;11(3):e0150188. doi: 10.1371/journal.pone.0150188
   PubMed Web of Science ®Google Scholar
• Albadri S, Del Bene F, Revenu C. Genome editing using CRISPR/Cas9-based knock-in approaches in zebrafish. Methods. 2017;121–122:77–85. doi: 10.1016/j.ymeth.2017.03.005
   PubMed Web of Science ®Google Scholar
• Rosello M, Serafini M, Concordet J-P, et al. Precise mutagenesis in zebrafish using cytosine base editors. Nat Protoc. 2023;18(9):2794–2813. doi: 10.1038/s41596-023-00854-3
   PubMedGoogle Scholar
• Ramesh T, Lyon AN, Pineda RH, et al. A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease. Dis Model Mech. 2010;3(9–10):652–662. doi: 10.1242/dmm.005538
   PubMed Web of Science ®Google Scholar
• Sakowski SA, Lunn JS, Busta AS, et al. Neuromuscular effects of G93A-SOD1 expression in zebrafish. Mol Neurodegener. 2012;7(1):44. doi: 10.1186/1750-1326-7-44
   PubMedGoogle Scholar
• Lemmens R, Van Hoecke A, Hersmus N, et al. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum Mol Genet. 2007;16(19):2359–2365. doi: 10.1093/hmg/ddm193
   PubMed Web of Science ®Google Scholar
• Da Costa MMJ, Allen CE, Higginbottom A, et al. A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening. Dis Model Mech. 2014;7:73–81. doi: 10.1242/dmm.012013
   PubMedGoogle Scholar
• McGown A, McDearmid JR, Panagiotaki N, et al. Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model. Ann Neurol. 2013;73(2):246–258. doi: 10.1002/ana.23780
   PubMed Web of Science ®Google Scholar
• Laird AS, Van Hoecke A, De Muynck L, et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLOS ONE. 2010;5(10):e13368. doi: 10.1371/journal.pone.0013368
   PubMed Web of Science ®Google Scholar
• Kabashi E, Lin L, Tradewell ML, et al. Gain and loss of function of als-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet. 2010;19(4):671–683. doi: 10.1093/hmg/ddp534
   PubMed Web of Science ®Google Scholar
• Schmid B, Hruscha A, Hogl S, et al. Loss of als-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc Natl Acad Sci USA. 2013;110(13):4986–4991. doi: 10.1073/pnas.1218311110
   PubMed Web of Science ®Google Scholar
• Hewamadduma CAA, Grierson AJ, Ma TP, et al. Tardbpl splicing rescues motor neuron and axonal development in a mutant tardbp zebrafish. Hum Mol Genet. 2013;22(12):2376–2386. doi: 10.1093/hmg/ddt082
   PubMed Web of Science ®Google Scholar
• Dormann D, Rodde R, Edbauer D, et al. Als-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. Embo J. 2010;29(16):2841–2857. doi: 10.1038/emboj.2010.143
   PubMed Web of Science ®Google Scholar
• Acosta JR, Goldsbury C, Winnick C, et al. Mutant human FUS is ubiquitously mislocalized and generates persistent stress granules in primary cultured transgenic zebrafish cells. Coulson EJ, editor. PLOS ONE. 2014;9(6):e90572. doi: 10.1371/journal.pone.0090572
   PubMedGoogle Scholar
• Kabashi E, Bercier V, Lissouba A, et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLOS Genet. 2011;7(8):e1002214. doi: 10.1371/journal.pgen.1002214
   PubMedGoogle Scholar
• Armstrong GAB, Drapeau P. Loss and gain of FUS function impair neuromuscular synaptic transmission in a genetic model of ALS. Hum Mol Genet. 2013;22(21):4282–4292. doi: 10.1093/hmg/ddt278
   PubMedGoogle Scholar
• Lebedeva S, de Jesus Domingues AM, Butter F, et al. Characterization of genetic loss-of-function of fus in zebrafish. RNA Biol. 2017;14(1):29–35. doi: 10.1080/15476286.2016.1256532
   PubMed Web of Science ®Google Scholar
• Bourefis A-R, Campanari M-L, Buee-Scherrer V, et al. Functional characterization of a FUS mutant zebrafish line as a novel genetic model for ALS. Neurobiol Dis. 2020;142:104935. doi: 10.1016/j.nbd.2020.104935
   PubMedGoogle Scholar
• Fortier G, Butti Z, Patten SA. Modelling C9orf72-related amyotrophic lateral sclerosis in zebrafish. Biomedicines. 2020;8(10):440. doi: 10.3390/biomedicines8100440
   PubMedGoogle Scholar
• Lee Y-B, Chen H-J, Peres JN, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5(5):1178–1186. doi: 10.1016/j.celrep.2013.10.049
   PubMed Web of Science ®Google Scholar
• Swinnen B, Bento-Abreu A, Gendron TF, et al. A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. Acta Neuropathol. 2018;135(3):427–443. doi: 10.1007/s00401-017-1796-5
   PubMedGoogle Scholar
• Ohki Y, Wenninger-Weinzierl A, Hruscha A, et al. Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration. Mol Neurodegener. 2017;12(1):6. doi: 10.1186/s13024-016-0146-8
   PubMedGoogle Scholar
• Swaminathan A, Bouffard M, Liao M, et al. Expression of C9orf72-related dipeptides impairs motor function in a vertebrate model. Hum Mol Genet. 2018;27(10):1754–1762. doi: 10.1093/hmg/ddy083
   PubMedGoogle Scholar
• Shaw MP, Higginbottom A, McGown A, et al. Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features. Acta Neuropathol Commun. 2018;6(1):125. doi: 10.1186/s40478-018-0629-7
   PubMedGoogle Scholar
• Ciura S, Lattante S, Le Ber I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol. 2013;74(2):180–187. doi: 10.1002/ana.23946
   PubMed Web of Science ®Google Scholar
• Yeh T-H, Liu H-F, Li Y-W, et al. C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Exp Neurol. 2018;304:114–124. doi: 10.1016/j.expneurol.2018.03.002
   PubMed Web of Science ®Google Scholar
• Butti Z, Pan YE, Giacomotto J, et al. Reduced C9orf72 function leads to defective synaptic vesicle release and neuromuscular dysfunction in zebrafish. Commun Biol. 2021;4(1):792. doi: 10.1038/s42003-021-02302-y
   PubMedGoogle Scholar
• Jaroszynska N, Salzinger A, Tsarouchas TM, et al. C9ORF72 deficiency results in degeneration of the zebrafish retina in vivo [Internet]. Neuroscience. 2023 [cited 2024 Feb 8]. Available from: http://biorxiv.org/lookup/doi/10.1101/2023.10.19.563041
   Google Scholar
• Picher-Martel V, Valdmanis PN, Gould PV, et al. From animal models to human disease: a genetic approach for personalized medicine in ALS. acta neuropathol commun. Acta Neuropathol Commun. 2016;4(1):70. doi: 10.1186/s40478-016-0340-5
   PubMed Web of Science ®Google Scholar
• Kang SH, Li Y, Fukaya M, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16(5):571–579. doi: 10.1038/nn.3357
   PubMed Web of Science ®Google Scholar
• Miller SJ, Zhang P, Glatzer J, et al. Astroglial transcriptome dysregulation in early disease of an ALS mutant SOD1 mouse model. J Neurogenet. 2017;31(1–2):37–48. doi: 10.1080/01677063.2016.1260128
   PubMed Web of Science ®Google Scholar
• Maniatis S, Äijö T, Vickovic S, et al. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science. 2019;364(6435):89–93. doi: 10.1126/science.aav9776
   PubMedGoogle Scholar
• MacLean M, López-Díez R, Vasquez C, et al. Neuronal–glial communication perturbations in murine SOD1G93A spinal cord. Commun Biol. 2022;5(1):177. doi: 10.1038/s42003-022-03128-y
   PubMedGoogle Scholar
• Filipi T, Matusova Z, Abaffy P, et al. Cortical glia in SOD1(G93A) mice are subtly affected by als-like pathology. Sci Rep. 2023;13(1):6538. doi: 10.1038/s41598-023-33608-y
   PubMedGoogle Scholar
• Canto MCD, Gurney ME. A low expressor line of transgenic mice carrying a mutant human Cu,Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol. 1997;93(6):537–550. doi: 10.1007/s004010050650
   PubMedGoogle Scholar
• Alexander GM, Erwin KL, Byers N, et al. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res. 2004;130(1–2):7–15. doi: 10.1016/j.molbrainres.2004.07.002
   PubMedGoogle Scholar
• Deitch JS, Alexander GM, Bensinger A, et al. Phenotype of transgenic mice carrying a very low copy number of the mutant human G93A superoxide dismutase-1 gene associated with amyotrophic lateral sclerosis. PLOS ONE. 2014;9(6):e99879. doi: 10.1371/journal.pone.0099879
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Becher MW, Lee MK, et al. ALS-Linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18(2):327–338. doi: 10.1016/S0896-6273(00)80272-X
   PubMed Web of Science ®Google Scholar
• Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial als-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14(6):1105–1116. doi: 10.1016/0896-6273(95)90259-7
   PubMed Web of Science ®Google Scholar
• Ripps ME, Huntley GW, Hof PR, et al. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 1995;92(3):689–693. doi: 10.1073/pnas.92.3.689
   PubMed Web of Science ®Google Scholar
• Jonsson PA, Graffmo KS, Brännström T, et al. Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1. J Neuropathol Exp Neurol. 2006;65(12):1126–1136. doi: 10.1097/01.jnen.0000248545.36046.3c
   PubMedGoogle Scholar
• Chang-Hong R, Wada M, Koyama S, et al. Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2005;194(1):203–211. doi: 10.1016/j.expneurol.2005.02.011
   PubMedGoogle Scholar
• Joyce PI, Mcgoldrick P, Saccon RA, et al. A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity. Hum Mol Genet. 2015;24(7):1883–1897. doi: 10.1093/hmg/ddu605
   PubMedGoogle Scholar
• AndrewG R, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996;13(1):43–47. doi: 10.1038/ng0596-43
   PubMedGoogle Scholar
• Fischer LR, Li Y, Asress SA, et al. Absence of SOD1 leads to oxidative stress in peripheral nerve and causes a progressive distal motor axonopathy. Exp Neurol. 2012;233(1):163–171. doi: 10.1016/j.expneurol.2011.09.020
   PubMed Web of Science ®Google Scholar
• Muller FL, Song W, Liu Y, et al. Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. Free Radical Biol Med. 2006;40(11):1993–2004. doi: 10.1016/j.freeradbiomed.2006.01.036
   PubMed Web of Science ®Google Scholar
• Nagai M, Aoki M, Miyoshi I, et al. Rats expressing human cytosolic copper–zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci. 2001;21(23):9246–9254. doi: 10.1523/JNEUROSCI.21-23-09246.2001
   PubMed Web of Science ®Google Scholar
• Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA. 2002;99(3):1604–1609. doi: 10.1073/pnas.032539299
   PubMed Web of Science ®Google Scholar
• Wegorzewska I, Bell S, Cairns NJ, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA. 2009;106(44):18809–18814. doi: 10.1073/pnas.0908767106
   PubMed Web of Science ®Google Scholar
• Stallings NR, Puttaparthi K, Luther CM, et al. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis. 2010;40(2):404–414. doi: 10.1016/j.nbd.2010.06.017
   PubMed Web of Science ®Google Scholar
• Xu Y-F, Gendron TF, Zhang Y-J, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30(32):10851–10859. doi: 10.1523/JNEUROSCI.1630-10.2010
   PubMed Web of Science ®Google Scholar
• Arnold ES, Ling S-C, Huelga SC, et al. Als-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci USA. 2013;110(8):E736–745. doi: 10.1073/pnas.1222809110
   PubMed Web of Science ®Google Scholar
• Swarup V, Phaneuf D, Bareil C, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134(9):2610–2626. doi: 10.1093/brain/awr159
   PubMed Web of Science ®Google Scholar
• Zhou H, Huang C, Chen H, et al. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. Cox GA, editor. PLOS Genet. 2010;6(3):e1000887. doi: 10.1371/journal.pgen.1000887
   PubMed Web of Science ®Google Scholar
• Wils H, Kleinberger G, Janssens J, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA. 2010;107(8):3858–3863. doi: 10.1073/pnas.0912417107
   PubMed Web of Science ®Google Scholar
• Shan X, Chiang P-M, Price DL, et al. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci USA. 2010;107(37):16325–16330. doi: 10.1073/pnas.1003459107
   PubMed Web of Science ®Google Scholar
• Janssens J, Wils H, Kleinberger G, et al. Overexpression of ALS-Associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol. 2013;48(1):22–35. doi: 10.1007/s12035-013-8427-5
   PubMed Web of Science ®Google Scholar
• Tsai K-J, Yang C-H, Fang Y-H, et al. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med. 2010;207(8):1661–1673. doi: 10.1084/jem.20092164
   PubMed Web of Science ®Google Scholar
• Cannon A, Yang B, Knight J, et al. Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. Acta Neuropathol. 2012;123(6):807–823. doi: 10.1007/s00401-012-0979-3
   PubMed Web of Science ®Google Scholar
• Igaz LM, Kwong LK, Lee EB, et al. Dysregulation of the als-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121(2):726–738. doi: 10.1172/JCI44867
   PubMed Web of Science ®Google Scholar
• Walker AK, Spiller KJ, Ge G, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130(5):643–660. doi: 10.1007/s00401-015-1460-x
   PubMed Web of Science ®Google Scholar
• Huang C, Tong J, Bi F, et al. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest. 2012;122(1):107–118. doi: 10.1172/JCI59130
   PubMed Web of Science ®Google Scholar
• Wu L-S, Cheng W-C, Shen C-K. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J Biol Chem. 2012;287(33):27335–27344. doi: 10.1074/jbc.M112.359000
   PubMed Web of Science ®Google Scholar
• Iguchi Y, Katsuno M, Niwa J, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136(5):1371–1382. doi: 10.1093/brain/awt029
   PubMed Web of Science ®Google Scholar
• Fratta P, Sivakumar P, Humphrey J, et al. Mice with endogenous TDP ‐43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. Embo J. 2018;37(11):e98684. doi: 10.15252/embj.201798684
   PubMedGoogle Scholar
• White MA, Kim E, Duffy A, et al. TDP-43 gains function due to perturbed autoregulation in a tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552–563. doi: 10.1038/s41593-018-0113-5
   PubMed Web of Science ®Google Scholar
• Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP knockin mouse model of ALS. Cell Rep. 2019;26(2):364–373.e4. doi: 10.1016/j.celrep.2018.12.045
   PubMedGoogle Scholar
• Huang S-L, Wu L-S, Lee M, et al. A robust TDP-43 knock-in mouse model of ALS. Acta Neuropathol Commun. 2020;8(1):3. doi: 10.1186/s40478-020-0881-5
   PubMed Web of Science ®Google Scholar
• Krus KL, Strickland A, Yamada Y, et al. Loss of stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. Cell Rep. 2022;39(13):111001. doi: 10.1016/j.celrep.2022.111001
   PubMedGoogle Scholar
• Baughn MW, Melamed Z, López-Erauskin J, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023;379(6637):1140–1149. doi: 10.1126/science.abq5622
   PubMed Web of Science ®Google Scholar
• Nolan M, Talbot K, Ansorge O. Pathogenesis of fus-associated ALS and FTD: insights from rodent models. acta neuropathol commun. Acta Neuropathol Commun. 2016;4(1):99. doi: 10.1186/s40478-016-0358-8
   PubMed Web of Science ®Google Scholar
• Sharma A, Lyashchenko AK, Lu L, et al. Als-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun. 2016;7(1):10465. doi: 10.1038/ncomms10465
   PubMedGoogle Scholar
• Scekic‐Zahirovic J, Sendscheid O, El Oussini H, et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. Embo J. 2016;35(10):1077–1097. doi: 10.15252/embj.201592559
   PubMed Web of Science ®Google Scholar
• Scekic-Zahirovic J, Oussini HE, Mersmann S, et al. Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of fus-associated amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133(6):887–906. doi: 10.1007/s00401-017-1687-9
   PubMedGoogle Scholar
• Devoy A, Kalmar B, Stewart M, et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in ‘FUSDelta14’ knockin mice. Brain. 2017;140(11):2797–2805. doi: 10.1093/brain/awx248
   PubMedGoogle Scholar
• Mitchell JC, McGoldrick P, Vance C, et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125(2):273–288. doi: 10.1007/s00401-012-1043-z
   PubMed Web of Science ®Google Scholar
• Shelkovnikova TA, Peters OM, Deykin AV, et al. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288(35):25266–25274. doi: 10.1074/jbc.M113.492017
   PubMedGoogle Scholar
• Huang C, Zhou H, Tong J, et al. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Cox GA, editor. PLOS Genet. 2011;7(3):e1002011. doi: 10.1371/journal.pgen.1002011
   PubMedGoogle Scholar
• Kino Y, Washizu C, Kurosawa M, et al. FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2015;3(1):24. doi: 10.1186/s40478-015-0202-6
   PubMedGoogle Scholar
• Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA [Internet]. 2013 [cited 2024 Feb 19]. Available from: https://pnas.org/doi/full/10.1073/pnas.1318835110
   Google Scholar
• O’Rourke JG, Bogdanik L, Muhammad AKMG, et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron. 2015;88(5):892–901. doi: 10.1016/j.neuron.2015.10.027
   PubMed Web of Science ®Google Scholar
• Koppers M, Blokhuis AM, Westeneng H, et al. C 9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol. 2015;78(3):426–438. doi: 10.1002/ana.24453
   PubMedGoogle Scholar
• O’Rourke JG, Bogdanik L, Yáñez A, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351(6279):1324–1329. doi: 10.1126/science.aaf1064
   PubMed Web of Science ®Google Scholar
• Atanasio A, Decman V, White D, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production and glomerulonephropathy in mice. Sci Rep. 2016;6(1):23204. doi: 10.1038/srep23204
   PubMedGoogle Scholar
• Burberry A, Suzuki N, Wang J-Y, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med [Internet]. 2016 [cited 2024 Feb 19]. Available from: https://www.science.org/doi/10.1126/scitranslmed.aaf6038
   PubMedGoogle Scholar
• Jiang J, Zhu Q, Gendron TF, et al. Gain of toxicity from ALS/FTD-Linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-Containing RNAs. Neuron. 2016;90(3):535–550. doi: 10.1016/j.neuron.2016.04.006
   PubMed Web of Science ®Google Scholar
• Ugolino J, Ji YJ, Conchina K, et al. Loss of C9orf72 enhances Autophagic activity via deregulated mTOR and TFEB signaling. Cox GA, editor. PLOS Genet. 2016;12(11):e1006443. doi: 10.1371/journal.pgen.1006443
   PubMed Web of Science ®Google Scholar
• Lopez-Herdoiza M-B, Bauché S, Wilmet B, et al. C9ORF72 knockdown triggers ftd-like symptoms and cell pathology in mice. Front Cell Neurosci. 2023;17:1155929. doi: 10.3389/fncel.2023.1155929
   PubMedGoogle Scholar
• Shao Q, Liang C, Chang Q, et al. C9orf72 deficiency promotes motor deficits of a C9ALS/FTD mouse model in a dose-dependent manner. acta neuropathol commun. Acta Neuropathol Commun. 2019;7(1):32. doi: 10.1186/s40478-019-0685-7
   PubMedGoogle Scholar
• Zhu Q, Jiang J, Gendron TF, et al. Reduced C9ORF72 function exacerbates gain of toxicity from als/ftd-causing repeat expansion in C9orf72. Nat Neurosci. 2020;23(5):615–624. doi: 10.1038/s41593-020-0619-5
   PubMed Web of Science ®Google Scholar
• Dong W, Ma Y, Guan F, et al. Ablation of C9orf72 together with excitotoxicity induces ALS in rats. FEBS J. 2021;288(5):1712–1723. doi: 10.1111/febs.15501
   PubMedGoogle Scholar
• Chew J, Gendron TF, Prudencio M, et al. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348(6239):1151–1154. doi: 10.1126/science.aaa9344
   PubMed Web of Science ®Google Scholar
• Chew J, Cook C, Gendron TF, et al. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol Neurodegener. 2019;14(1):9. doi: 10.1186/s13024-019-0310-z
   PubMedGoogle Scholar
• Herranz-Martin S, Chandran J, Lewis K, et al. Viral delivery of C9ORF72 hexanucleotide repeat expansions in mice lead to repeat length dependent neuropathology and behavioral deficits. Disease Model Mechanisms. 2017:dmm.029892. doi: 10.1242/dmm.029892
   PubMedGoogle Scholar
• Riemslagh FW, Van Der Toorn EC, Verhagen RFM, et al. Inducible expression of human C9ORF72 36× G4C2 hexanucleotide repeats is sufficient to cause RAN translation and rapid muscular atrophy in mice. Disease Model Mechanisms. 2021;14(2):dmm044842. doi: 10.1242/dmm.044842
   PubMedGoogle Scholar
• O’Reilly LP, Luke CJ, Perlmutter DH, et al. C. elegans in high-throughput drug discovery. Adv Drug Deliv Rev. 2014;69–70:247–253. doi: 10.1016/j.addr.2013.12.001
   PubMed Web of Science ®Google Scholar
• Dibaj P, Zschüntzsch J, Steffens H, et al. Influence of methylene blue on microglia-induced inflammation and motor neuron degeneration in the SOD1G93A model for ALS. Block ML, editor. PLOS ONE. 2012;7(8):e43963. doi: 10.1371/journal.pone.0043963
   PubMedGoogle Scholar
• Patten SA, Aggad D, Martinez J, et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight. 2017;2(22). doi: 10.1172/jci.insight.97152
   PubMedGoogle Scholar
• Bose P, Tremblay E, Maios C, et al. The novel small molecule TRVA242 stabilizes neuromuscular junction defects in multiple animal models of amyotrophic lateral sclerosis. Neurotherapeutics. 2019;16(4):1149–1166. doi: 10.1007/s13311-019-00765-w
   PubMedGoogle Scholar
• Wong SQ, Pontifex MG, Phelan MM, et al. α-methyl-α-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-43 proteinopathy. Neurobiol Dis. 2018;118:40–54. doi: 10.1016/j.nbd.2018.06.013
   PubMedGoogle Scholar
• Labarre A, Guitard E, Tossing G, et al. Fatty acids derived from the probiotic Lacticaseibacillus rhamnosus HA-114 suppress age-dependent neurodegeneration. Commun Biol. 2022;5(1):1340. doi: 10.1038/s42003-022-04295-8
   PubMed Web of Science ®Google Scholar
• Tossing G, Livernoche R, Maios C, et al. Genetic and pharmacological PARP inhibition reduces axonal degeneration in C. elegans models of ALS. Hum Mol Genet. 2022;31(19):3313–3324. doi: 10.1093/hmg/ddac116
   PubMedGoogle Scholar
• Silva MC, Fox S, Beam M, et al. A genetic screening strategy identifies novel regulators of the proteostasis network. Serio TR, editor. PLOS Genet. 2011;7(12):e1002438. doi: 10.1371/journal.pgen.1002438
   PubMedGoogle Scholar
• Boyd JD, Lee-Armandt JP, Feiler MS, et al. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. SLAS Discov. 2014;19(1):44–56. doi: 10.1177/1087057113501553
   Google Scholar
• Tseng Y-L, Lu P-C, Lee C-C, et al. Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera. J Biomed Sci. 2023;30(1):27. doi: 10.1186/s12929-023-00921-7
   PubMedGoogle Scholar
• Ikenaka K, Kawai K, Katsuno M, et al. Dnc-1/dynactin 1 knockdown disrupts transport of autophagosomes and induces motor neuron degeneration. Pandey U, editor. PLOS ONE. 2013;8(2):e54511. doi: 10.1371/journal.pone.0054511
   PubMedGoogle Scholar
• Ikenaka K, Tsukada Y, Giles AC, et al. A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease. Sci Rep. 2019;9(1):10104. doi: 10.1038/s41598-019-46642-6
   PubMedGoogle Scholar
• McGown A, Shaw DPJ, Ramesh T. Znstress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis. Mol Neurodegener. 2016;11(1):56. doi: 10.1186/s13024-016-0122-3
   PubMedGoogle Scholar
• Joardar A, Menzl J, Podolsky TC, et al. PPAR gamma activation is neuroprotective in a drosophila model of ALS based on TDP-43. Hum Mol Genet. 2015;24(6):1741–1754. doi: 10.1093/hmg/ddu587
   PubMed Web of Science ®Google Scholar
• Dupuis L, Dengler R, Heneka MT, et al. A randomized, Double Blind, placebo-controlled trial of Pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. Sensi SL, editor. PLOS ONE. 2012;7(6):e37885. doi: 10.1371/journal.pone.0037885
   PubMed Web of Science ®Google Scholar
• Wang T, Cheng J, Wang S, et al. α-Lipoic acid attenuates oxidative stress and neurotoxicity via the ERK/Akt-dependent pathway in the mutant hSOD1 related drosophila model and the NSC34 cell line of amyotrophic lateral sclerosis. Brain Res Bull. 2018;140:299–310. doi: 10.1016/j.brainresbull.2018.05.019
   PubMedGoogle Scholar
• Lee D, Jeong HC, Kim SY, et al. A comparison study of pathological features and drug efficacy between drosophila models of C9orf72 ALS/FTD. Mol Cells. 2024;47(1):100005. doi: 10.1016/j.mocell.2023.12.003
   PubMedGoogle Scholar
• Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56–61. doi: 10.1038/nature14973
   PubMed Web of Science ®Google Scholar
• Maragakis NJ, de Carvalho M, Weiss MD. Therapeutic targeting of ALS pathways: refocusing an incomplete picture. Ann Clin Transl Neurol. 2023;10(11):1948–1971. doi: 10.1002/acn3.51887
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39(2):147–157. doi: 10.1002/ana.410390203
   PubMed Web of Science ®Google Scholar
• Desnuelle C, Dib M, Garrel C, et al. A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2001;2(1):9–18. doi: 10.1080/146608201300079364
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5(3):347–350. doi: 10.1038/6568
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology. 2004;63(9):1656–1661. doi: 10.1212/01.WNL.0000142992.81995.F0
   PubMed Web of Science ®Google Scholar
• Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2015;354(1–2):70–74. doi: 10.1016/j.jns.2015.04.052
   PubMed Web of Science ®Google Scholar
• Oki R, Izumi Y, Fujita K, et al. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2022;79(6):575. doi: 10.1001/jamaneurol.2022.0901
   PubMedGoogle Scholar
• Gurney ME, Fleck TJ, Himes CS, et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998;50(1):62–66. doi: 10.1212/WNL.50.1.62
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213(2):448–455. doi: 10.1016/j.expneurol.2008.07.017
   PubMed Web of Science ®Google Scholar
• Aoki M, Warita H, Mizuno H, et al. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 2011;1382:321–325. doi: 10.1016/j.brainres.2011.01.058
   PubMed Web of Science ®Google Scholar
• Yan J, Wang YM, Hellwig A, et al. TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS. Cell Rep Med. 2024;5(2):101413. doi: 10.1016/j.xcrm.2024.101413
   PubMedGoogle Scholar
• Wang I-F, Guo B-S, Liu Y-C, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci USA. 2012;109(37):15024–15029. doi: 10.1073/pnas.1206362109
   PubMed Web of Science ®Google Scholar
• Crisafulli SG, Brajkovic S, Cipolat Mis MS, et al. Therapeutic strategies under development targeting inflammatory mechanisms in amyotrophic lateral sclerosis. Mol Neurobiol. 2018;55(4):2789–2813. doi: 10.1007/s12035-017-0532-4
   PubMed Web of Science ®Google Scholar
• Schütz B, Reimann J, Dumitrescu-Ozimek L, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005;25(34):7805–7812. doi: 10.1523/JNEUROSCI.2038-05.2005
   PubMed Web of Science ®Google Scholar
• Kiaei M, Kipiani K, Chen J, et al. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2005;191(2):331–336. doi: 10.1016/j.expneurol.2004.10.007
   PubMed Web of Science ®Google Scholar
• Shibata N, Kawaguchi‐Niida M, Yamamoto T, et al. Effects of the PPARγ activator pioglitazone on p38 MAP kinase and IκBα in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology. 2008;28(4):387–398. doi: 10.1111/j.1440-1789.2008.00890.x
   PubMed Web of Science ®Google Scholar
• Pelaez MC, Desmeules A, Gelon PA, et al. Neuronal dysfunction caused by FUSR521G promotes als-associated phenotypes that are attenuated by nf-κB inhibition. Acta Neuropathol Commun. 2023;11(1):182. doi: 10.1186/s40478-023-01671-1
   PubMedGoogle Scholar
• Chen Y, Wang H, Ying Z, et al. Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through tfeb-mediated autophagy and lysosomal biogenesis: the new molecular mechanism of ibudilast and its implication for neuroprotective therapy. Biochem Biophys Res Commun. 2020;526(1):231–238. doi: 10.1016/j.bbrc.2020.03.051
   PubMed Web of Science ®Google Scholar
• López-Blanch R, Salvador-Palmer R, Oriol-Caballo M, et al. Nicotinamide riboside, pterostilbene and ibudilast protect motor neurons and extend survival in ALS mice. Neurotherapeutics. 2024;21(1):e00301. doi: 10.1016/j.neurot.2023.10.011
   PubMedGoogle Scholar
• Wu C, Watts ME, Rubin LL. MAP4K4 activation mediates motor neuron degeneration in amyotrophic lateral sclerosis. Cell Rep. 2019;26(5):1143–1156.e5. doi: 10.1016/j.celrep.2019.01.019
   PubMedGoogle Scholar
• Liu M-L, Ma S, Tai W, et al. Screens in aging-relevant human als-motor neurons identify MAP4Ks as therapeutic targets for the disease. Cell Death Dis. 2024;15(1):4. doi: 10.1038/s41419-023-06395-7
   PubMedGoogle Scholar
• Trias E, Ibarburu S, Barreto-Núñez R, et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13(1):177. doi: 10.1186/s12974-016-0620-9
   PubMedGoogle Scholar
• Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019;20(1):19–33. doi: 10.1038/s41583-018-0093-1
   PubMed Web of Science ®Google Scholar
• Ito Y, Ofengeim D, Najafov A, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353(6299):603–608. doi: 10.1126/science.aaf6803
   PubMed Web of Science ®Google Scholar
• Wang S-M, Wu H-E, Yasui Y, et al. Nucleoporin POM121 signals tfeb-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine. Autophagy. 2023;19(1):126–151. doi: 10.1080/15548627.2022.2063003
   PubMed Web of Science ®Google Scholar
• Ionescu A, Gradus T, Altman T, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A Model. Cell Death Dis. 2019;10(3):210. doi: 10.1038/s41419-019-1451-2
   PubMedGoogle Scholar
• Smith RA. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Investigation. 2006;116(8):2290–2296. doi: 10.1172/JCI25424
   PubMed Web of Science ®Google Scholar
• McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Investigation. 2018;128(8):3558–3567. doi: 10.1172/JCI99081
   PubMed Web of Science ®Google Scholar
• Liu Y, Dodart J-C, Tran H, et al. Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nat Commun. 2021;12(1):847. doi: 10.1038/s41467-021-21112-8
   PubMedGoogle Scholar
• Tran H, Moazami MP, Yang H, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2022;28(1):117–124. doi: 10.1038/s41591-021-01557-6
   PubMedGoogle Scholar
• Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28(1):104–116. doi: 10.1038/s41591-021-01615-z
   PubMed Web of Science ®Google Scholar
• Droppelmann CA, Campos-Melo D, Noches V, et al. Mitigation of TDP-43 toxic phenotype by an RGNEF fragment in amyotrophic lateral sclerosis models. Brain. 2024;147(6):2053–2068. doi: 10.1093/brain/awae078
   PubMedGoogle Scholar
• Becker LA, Huang B, Bieri G, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367–371. doi: 10.1038/nature22038
   PubMed Web of Science ®Google Scholar
• Ma ZC, Moore HJ, Smith TJ, et al. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins. Nat Commun. 2023;14(1):6492. doi: 10.1038/s41467-023-42147-z
   PubMedGoogle Scholar
• Ediriweera GR, Chen L, Yerbury JJ, et al. Non-viral vector-mediated gene therapy for ALS: challenges and future perspectives. Mol Pharm. 2021;18(6):2142–2160. doi: 10.1021/acs.molpharmaceut.1c00297
   PubMedGoogle Scholar
• Chen L, Watson C, Morsch M, et al. Improving the delivery of SOD1 antisense oligonucleotides to motor neurons using calcium phosphate-lipid nanoparticles. Front Neurosci. 2017;11:476. doi: 10.3389/fnins.2017.00476
   PubMed Web of Science ®Google Scholar
• Poulin-Brière A, Rezaei E, Pozzi S. Antibody-based therapeutic interventions for amyotrophic lateral sclerosis: a systematic literature review. Front Neurosci. 2021;15:790114. doi: 10.3389/fnins.2021.790114
   PubMedGoogle Scholar
• Minamiyama S, Sakai M, Yamaguchi Y, et al. Efficacy of oligodendrocyte precursor cells as delivery vehicles for single-chain variable fragment to misfolded SOD1 in ALS rat model. Mol Ther - Methods Clin Devel. 2023;28:312–329. doi: 10.1016/j.omtm.2023.01.008
   PubMedGoogle Scholar
• Lincecum JM, Vieira FG, Wang MZ, et al. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet. 2010;42(5):392–399. doi: 10.1038/ng.557
   PubMedGoogle Scholar
• Andrews-Zwilling Y, Mathur V, Kuhn L, et al. Inhibiting C1q improves compound muscle action potential and reduces neuronal damage in the SOD1G93A mouse Model (P1-13.004). Neurology. 2022;98(18_supplement). doi: 10.1212/WNL.98.18_supplement.3302
   Google Scholar
• Fisher EMC, Greensmith L, Malaspina A, et al. Opinion: more mouse models and more translation needed for ALS. Mol Neurodegener. 2023;18(1):30. doi: 10.1186/s13024-023-00619-2
   PubMedGoogle Scholar
• Wong C, Stavrou M, Elliott E, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3(4):fcab242. doi: 10.1093/braincomms/fcab242
   PubMedGoogle Scholar
• Díaz-García D, Ferrer-Donato Á, Méndez-Arriaga JM, et al. Design of mesoporous silica nanoparticles for the treatment of amyotrophic lateral sclerosis (ALS) with a therapeutic cocktail based on leptin and pioglitazone. ACS Biomater Sci Eng. 2022;8(11):4838–4849. doi: 10.1021/acsbiomaterials.2c00865
   PubMedGoogle Scholar
• Lu Y, Wang J-W, Li N, et al. Intranasal administration of edaravone nanoparticles improves its stability and brain bioavailability. J Control Release. 2023;359:257–267. doi: 10.1016/j.jconrel.2023.06.001
   PubMedGoogle Scholar
• Medina DX, Chung EP, Teague CD, et al. Intravenously administered, retinoid activating nanoparticles increase lifespan and reduce neurodegeneration in the SOD1G93A mouse model of ALS. Front Bioeng Biotechnol. 2020;8:224. doi: 10.3389/fbioe.2020.00224
   PubMedGoogle Scholar
• Evans MC, Gaillard PJ, De Boer M, et al. Cns-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis. acta neuropathol commun. Acta Neuropathol Commun. 2014;2(1):66. doi: 10.1186/2051-5960-2-66
   PubMedGoogle Scholar
• Wiley NJ, Madhankumar AB, Mitchell RM, et al. Lipopolysaccharide modified liposomes for amyotropic lateral sclerosis therapy: efficacy in SOD1 mouse model. ANP. 2012;1(3):44–53. doi: 10.4236/anp.2012.13007
   Google Scholar
• Vasta R, Chia R, Traynor BJ, et al. Unraveling the complex interplay between genes, environment, and climate in ALS. EBioMedicine. 2022;75:103795. doi: 10.1016/j.ebiom.2021.103795
   PubMed Web of Science ®Google Scholar
• Hawrot J, Imhof S, Wainger BJ. Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs. Neurobiol Dis. 2020;134:104680. doi: 10.1016/j.nbd.2019.104680
   PubMed Web of Science ®Google Scholar
• Fujimori K, Ishikawa M, Otomo A, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med. 2018;24(10):1579–1589. doi: 10.1038/s41591-018-0140-5
   PubMed Web of Science ®Google Scholar